ArticleBMJ public health2026
Implementation of next-generation sequencing to guide care and public health action in settings with high burden of rifampicin-resistant tuberculosis: 32 stakeholder consensus statements generated using Delphi principles.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comprehensive knowledge of resistance to the novel all-oral regimens for treatment of rifampicin-resistant tuberculosis (RR-TB) is important, but challenging variant detection by next-generation sequencing (NGS) in combination with variant interpretation software can diagnose resistance early. We aimed to generate a consensus on strategic issues for the implementation of NGS for routine RR-TB care. Methods: We employed a stakeholder consensus process informed by Delphi principles. First, stakeholders participated in an online survey to provide feedback on statements using a 3-point Likert scale and free text. Responses were then summarised and follow-up discussion fora with stakeholders were held to revise statements until a consensus was reached. Findings: Of the 116 invited stakeholders, 58 participated, representing RR-TB research (n=28), clinical care (n=11), diagnosis (n=5), RR-TB survivors and advocacy communities (n=5) from 14 countries in five of the six WHO regions. A consensus was rapidly reached for most statements with limited editorial changes needed. The debate mostly focused on statements covering performing sequencing at centralised facilities, acting on variants without statistical association with resistance in the WHO catalogue of mutations, strengthening WHO-endorsed regimens and the need for informed consent for the use of NGS for care and surveillance. Interpretation: The consensus-building process grounded in real-world experience from a diverse group of stakeholders generated 32 consensus statements covering five strategic domains. The blueprint generated is not a definite prescriptive framework but a document that can support policymakers when developing country-specific policies for NGS-guided precision medicine and RR-TB care. Sources of funding: This work was supported by the Global Health EDCTP3 Joint Undertaking and the Bill & Melinda Gates Foundation under the GenPath Africa project (101103171), the Research Foundation Flanders (FWO) Odysseus (G0F8316N) and TBM grants (T001018N).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.